Sales of Pfizer's Procardia XL, 1990-2000

From: Achieving Market Dominance Through Reformulation. Source: Authors research & analysis, company reports
Created for Global User, Novartis- Global License. IP Address: 160.62.4.10
© Business Insights Limited, 2001
 Estimated market share of commercialised reformulation systems, 2001

From: Achieving Market Dominance Through Reformulation. Source: Authors research & analysis
Created for Global User, Novartis- Global License. IP Address: 160.62.4.10
© Business Insights Limited, 2001
 Market forces affecting pharmaceutical reformulation

From: Achieving Market Dominance Through Reformulation. Source: Authors research & analysis
Created for Global User, Novartis- Global License. IP Address: 160.62.4.10
© Business Insights Limited, 2001
 Theoretical representation of a pharmaceutical strategy to optimise
R&D for the designated compound and related multiple reformulation-
based products

From: Achieving Market Dominance Through Reformulation. Source: Authors research & analysis
Created for Global User, Novartis- Global License. IP Address: 160.62.4.10
© Business Insights Limited, 2001
 Revenue and patent protection achieved through reformulation of one
key drug

From: Achieving Market Dominance Through Reformulation. Source: Authors research & analysis
Created for Global User, Novartis- Global License. IP Address: 160.62.4.10
© Business Insights Limited, 2001
 Reformulation development timeplan showing patent extension and
protection possibilities through multiple reformulation products

From: Achieving Market Dominance Through Reformulation. Source: Authors research & analysis
Created for Global User, Novartis- Global License. IP Address: 160.62.4.10
© Business Insights Limited, 2001
 R&D pipeline reformulation focus, 2001

From: Achieving Market Dominance Through Reformulation. Source: Datamonitor, Authors research & analysis
Created for Global User, Novartis- Global License. IP Address: 160.62.4.10
© Business Insights Limited, 2001
 CAGR of major reformulation sectors, 2000-2005

From: Achieving Market Dominance Through Reformulation. Source: Datamonitor, Authors research & analysis
Created for Global User, Novartis- Global License. IP Address: 160.62.4.10
© Business Insights Limited, 2001
 Commercial benefits of reformulation

From: Achieving Market Dominance Through Reformulation. Source: Authors research & analysis
Created for Global User, Novartis- Global License. IP Address: 160.62.4.10
© Business Insights Limited, 2001
 Theoretical reformulation strategy for research-based companies to
sustain market leadership

From: Achieving Market Dominance Through Reformulation. Source: Authors research & analysis
Created for Global User, Novartis- Global License. IP Address: 160.62.4.10
© Business Insights Limited, 2001
 Global sales of BMS' Capotent, 1993-2000

From: Achieving Market Dominance Through Reformulation. Source: Authors research & analysis, company reports
Created for Global User, Novartis- Global License. IP Address: 160.62.4.10
© Business Insights Limited, 2001
 Economic and commercial advantages of branded drugs

From: Achieving Market Dominance Through Reformulation. Source: Authors research & analysis
Created for Global User, Novartis- Global License. IP Address: 160.62.4.10
© Business Insights Limited, 2001